JP2003531129A5 - - Google Patents

Download PDF

Info

Publication number
JP2003531129A5
JP2003531129A5 JP2001576078A JP2001576078A JP2003531129A5 JP 2003531129 A5 JP2003531129 A5 JP 2003531129A5 JP 2001576078 A JP2001576078 A JP 2001576078A JP 2001576078 A JP2001576078 A JP 2001576078A JP 2003531129 A5 JP2003531129 A5 JP 2003531129A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
immunoglobulin
antigen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001576078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003531129A (ja
Filing date
Publication date
Priority claimed from US09/748,960 external-priority patent/US20010046496A1/en
Application filed filed Critical
Publication of JP2003531129A publication Critical patent/JP2003531129A/ja
Publication of JP2003531129A5 publication Critical patent/JP2003531129A5/ja
Withdrawn legal-status Critical Current

Links

JP2001576078A 2000-04-14 2001-04-13 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用 Withdrawn JP2003531129A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55008200A 2000-04-14 2000-04-14
US09/550,082 2000-04-14
US09/748,960 2000-12-27
US09/748,960 US20010046496A1 (en) 2000-04-14 2000-12-27 Method of administering an antibody
PCT/US2001/012234 WO2001078779A2 (en) 2000-04-14 2001-04-13 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012105379A Division JP5764524B2 (ja) 2000-04-14 2012-05-02 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用

Publications (2)

Publication Number Publication Date
JP2003531129A JP2003531129A (ja) 2003-10-21
JP2003531129A5 true JP2003531129A5 (enExample) 2011-02-17

Family

ID=27069332

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001576078A Withdrawn JP2003531129A (ja) 2000-04-14 2001-04-13 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用
JP2012105379A Expired - Lifetime JP5764524B2 (ja) 2000-04-14 2012-05-02 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用
JP2015007655A Expired - Lifetime JP6021959B2 (ja) 2000-04-14 2015-01-19 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012105379A Expired - Lifetime JP5764524B2 (ja) 2000-04-14 2012-05-02 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用
JP2015007655A Expired - Lifetime JP6021959B2 (ja) 2000-04-14 2015-01-19 炎症性腸疾患を治療するための抗体α４β７インテグリンおよびその使用

Country Status (15)

Country Link
US (5) US20010046496A1 (enExample)
EP (3) EP1278543B1 (enExample)
JP (3) JP2003531129A (enExample)
AU (1) AU2001251629A1 (enExample)
BE (1) BE2017C009I2 (enExample)
CA (1) CA2406220C (enExample)
CY (3) CY1113489T1 (enExample)
DK (2) DK1278543T3 (enExample)
ES (2) ES2398096T3 (enExample)
FR (1) FR14C0080I2 (enExample)
LU (1) LUC00014I2 (enExample)
MX (1) MXPA02010059A (enExample)
NL (1) NL300702I1 (enExample)
PT (1) PT2298348T (enExample)
WO (1) WO2001078779A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
KR20040105740A (ko) * 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
DOP2005000002A (es) * 2004-01-09 2005-08-15 Pfizer "anticuerpos contra madcam"
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
PE20070374A1 (es) * 2005-07-08 2007-05-12 Pfizer Ltd ANTICUERPOS ANTI-MAdCAM
EP1904100A1 (en) * 2005-07-11 2008-04-02 Pfizer Limited New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
AU2008204433B2 (en) * 2007-01-11 2014-03-13 Novo Nordisk A/S Anti-KIR antibodies, formulations, and uses thereof
US20100297699A1 (en) * 2007-03-20 2010-11-25 Millennium Pharmaceuticals, Inc. Nucleic Acids Encoding Humanized Immunoglobulin That Binds Alpha4Beta7 Integrin
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
PE20120497A1 (es) * 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
WO2013078375A2 (en) * 2011-11-23 2013-05-30 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
EA034583B1 (ru) * 2012-01-12 2020-02-21 Милленниум Фармасьютикалз, Инк. ПРИМЕНЕНИЯ АНТИ-α4β7 АНТИТЕЛА
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
EP3430052A2 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
MA43755A (fr) 2016-03-14 2018-11-28 Millennium Pharm Inc Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
JP7162533B2 (ja) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患の治療を目的とする三剤併用療法
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
KR102787394B1 (ko) 2017-07-14 2025-03-26 화이자 인크. MAdCAM에 대한 항체
US12643950B1 (en) 2019-02-07 2026-06-02 Takeda Pharmaceutical Company Limited Autoinjector comprising high concentration formulation of vedolizumab
US12492245B2 (en) * 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5403919A (en) * 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ES2319831T3 (es) * 1998-09-14 2009-05-12 Board Of Regents, The University Of Texas System Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8221749B2 (en) 2008-02-20 2012-07-17 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Similar Documents

Publication Publication Date Title
CN104684552B (zh) 组合及其用途
JP2022543612A5 (enExample)
JP2025172841A5 (enExample)
JP2020002171A5 (enExample)
JP2022120009A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2013166765A5 (enExample)
JP2009519257A5 (enExample)
JP2022531408A5 (enExample)
JP2017537105A5 (enExample)
WO2001078779A3 (en) Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
JP2002524529A5 (enExample)
WO2016180958A1 (en) Treatment for multiple myeloma (mm)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2023546503A5 (enExample)
JP2022514561A5 (enExample)
JP2024521105A5 (enExample)
Gobel Hypersensitivity reactions to biological drugs
JP2022534494A5 (enExample)
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
JP2022547061A5 (enExample)
CN114423455A (zh) 用于治疗系统性硬化症的药物组合物
JP2024526742A5 (enExample)
JP2024522620A5 (enExample)
JP2024509385A5 (enExample)
JP2023534576A5 (enExample)